1. Tumor regression grade (TRG) (Time Frame - immediately after the surgery): Tumor regression will be centrally graded according to the grading system developed by Dworak et al (Dworak, Keilholz et al. 1997).
Secondary outcome:
1. Safety and tolerability (acc. to NCI CTC AE v5.0) incl. vital signs, clinical parameters and overall feasibility of the regimen (Time Frame - max 54 months): Safety assessments will include physical examinations including visual and skin assessment as well as vital signs (blood pressure, heart rate, respiratory rate), performance status (ECOG), clinical laboratory profile, 12-lead ECG and ECHO, ophthalmologic assessment, concomitant medication/therapies/procedures and adverse events. All observed adverse events will be graded according to NCI CTCAE v5. Adverse events will be analysed overall and concerning their potential relationship to study treatment and surgical intervention. Serious adverse events (SAE) will be analysed in the same way.
2. Perioperative morbidity and mortality (Time Frame - max 24 months): Perioperative morbidity and mortality are defined as prolongation of hospitalization (discharge >20 days after surgery), re-hospitalization or reoperation under general anaesthesia within 30 days of surgery or death during surgery or within 30 days of surgery; Other severe postoperative complications within 30 days of surgery including surgery-associated bleeding with replacement ≥ 4 units of erythrocyte concentrates, transient liver failure, defined as a bilirubin level >10 mg/dL lasting > 7 days, renal failure requiring dialysis, respiratory failure with renewed necessary mechanical ventilation or >26 h, necessary mechanical ventilation, deep venous thromboembolism, cardiac failure, major impaired wound healing necessitating re-operation or prolonging hospitalization (discharge >20 days after surgery); >8 weeks delay of surgery due to study treatment-related toxicity; and further.
3. R0-resection rate (Time Frame - max 24 months): The R0 resection rate will be determined as the rate of R0 resections out of all resected patients. In addition, the R1 and/or R2 resection rates will be determined.
4. Overall Response Rate (ORR) according to RECIST v1.1 (Time Frame - max 54 months): Response rate to preoperative treatment will be assessed according to RECIST v1.1.
5. Disease free survival (Time Frame - max 54 months): Disease free survival will be determined as time from start of study treatment to date of first observed disease recurrence (either local or distant) or death from any cause.
6. Overall survival (OS) (Time Frame - max 54 months): Overall survival will be determined as time from start of study treatment to date of death from any cause.
7. Translational research 1 (Time Frame - max 54 months): Correlation of quantitative BRAF V600E levels (measured by ddPCR) with TRG
8. Translational research 2 (Time Frame - max 54 months): Evaluation of mechanism of relative resistance in patients with less response (evaluated by tumor and liquid biopsy NGS profiling at baseline and after treatment)
9. Translational research 3 (Time Frame - max 54 months): Comparison of ctDNA clearance and TRG with a BRAF mutant/pMMR cohort from the planned neoadjuvant PROTECTOR study receiving neoadjuvant chemotherapy